Browsing Tag

Partnering

580 posts

GSK Signs T-Cell Manufacturing Deal
By

By
GlaxoSmithKline (GSK) has signed a three-year clinical manufacturing agreement with Hitachi Chemical Advanced Therapeutics Solutions (HCATS), an Allendale, New Jersey-based contract development and manufacturing organization. Under the agreement, HCATS will…

Merck & Co. Partners in $695-Million Deal for Cancer Immunotherapies
By

By
Merck & Co. and Dragonfly Therapeutics, a Waltham, Massachusetts-based company specializing in cancer immunotherapies, have partnered to discover, develop, and commercialize immunotherapies for patients with solid tumor cancers in a…

Roche To Acquire Immuno-Oncology Company Tusk Therapeutics in $759-Million Deal
By

By
Roche has acquired Tusk Therapeutics, a Stevenage, UK-based pharmaceutical company focused on immuno-oncology, in a deal worth up to EUR 659 million ($759 million) ($80 million upfront and $675 million).…

Merck & Co., Amazon, Accenture Partner for Cloud-Based Research Platform
By

By
Merck & Co. and Accenture, a management consulting company, have partnered with Amazon Web Services (AWS) to launch a cloud-based informatics research platform designed to help organizations in the life-sciences…

Otsuka Partners to Bring Smart Pill to Market
By

By
Otsuka America Pharmaceutical, which received US Food and Drug Administration (FDA) approval for a so-called “smart pill” in 2017, has formed a partnership to support the marketing in the US…

Pfizer in $425-Million mRNA-Based Vaccine Pact with Biopharm Company
By

By
Pfizer has formed a multi-year research and development deal worth up to $425 million with BioNTech AG, a Mainz, Germany-based biopharmaceutical company focused on immunotherapies for treating cancer and infectious…

Pfizer, Antares Pharma Partner to Develop Combination Drug Rescue Pen
By

By
Pfizer has formed a deal with Antares Pharma, an Ewing, New Jersey-based pharmaceutical company, to develop a combination drug-device rescue pen. This rescue pen will use the Antares QuickShot auto…

Regeneron Takes $100 Million Equity Stake in bluebird bio; To Develop Cancer Cell Therapies
By

By
Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company, and bluebird bio, a Cambridge, Massachusetts-based clinical-stage gene-therapy company, have partnered to apply their technology platforms to the discovery, development, and commercialization…

GSK, 23andMe in Pact for Genetic Drug Development
By

By
GlaxoSmithKline (GSK) and 23andMe, a Mountain View, California-headquartered personal genomics and biotechnology company, have partnered for an exclusive four-year pact that will focus on research and development of new medicines…

Gilead’s Kite Pharma, Gadeta in Cell Therapy Pact
By

By
Kite Pharma, Gilead Sciences’ cell-therapy subsidiary, and Gadeta, an Utrecht, Netherlands-based company developing cancer immunotherapies based on gamma delta T cell receptors (TCRs), have formed a pact to develop gamma delta…